A5082007334- Acute Lymphoblastic Leukemia research
- Childhood Cancer Survivors' Quality of Life
- Neuroblastoma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Adolescent and Pediatric Healthcare
- Acute Myeloid Leukemia Research
- Cancer therapeutics and mechanisms
- Chronic Myeloid Leukemia Treatments
- Neuroendocrine Tumor Research Advances
- Hematopoietic Stem Cell Transplantation
- Ethics in Clinical Research
- Cancer Treatment and Pharmacology
- CNS Lymphoma Diagnosis and Treatment
- Lung Cancer Research Studies
- Viral-associated cancers and disorders
- PARP inhibition in cancer therapy
- Chemotherapy-induced cardiotoxicity and mitigation
- Advanced Breast Cancer Therapies
- Cancer, Hypoxia, and Metabolism
- Ethics and Legal Issues in Pediatric Healthcare
- Retinoids in leukemia and cellular processes
- Chemotherapy-related skin toxicity
- Pharmaceutical studies and practices
Cincinnati Children's Hospital Medical Center
2018-2025
University of Cincinnati Medical Center
2018-2025
University of Cincinnati
2018-2023
Rainbow Babies & Children's Hospital
2013-2021
University Hospitals of Cleveland
2015-2016
Boston Children's Hospital
2012-2015
Children's Hospital of Philadelphia
2003-2014
University Hospitals Cleveland Medical Center
2014
Adherent Technologies (United States)
2009
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
2003
Combining venetoclax, a selective BCL2 inhibitor, with low-dose navitoclax, BCL-XL/BCL2 may allow targeting of both and BCL-XL without dose-limiting thrombocytopenia associated navitoclax monotherapy. The safety preliminary efficacy venetoclax chemotherapy was assessed in this phase I dose-escalation study (NCT03181126) pediatric adult patients relapsed/refractory (R/R) acute lymphoblastic leukemia or lymphoma. Forty-seven received treatment. A recommended II dose 50 mg for adults 25 <45 kg...
Purpose: Children with the rare Wilms tumor (WT)-aniridia (WAGR) syndrome have not had systematic evaluation of their clinical and pathologic features. We compared demographics, disease characteristics, treatment outcomes in a large cohort WT patients who did or WAGR syndrome. Patients Methods: Clinical pathology records were reviewed for 8,533 enrolled between 1969 2002 by National Tumor Study Group. Results: Sixty-four (0.75%) For non-WAGR patients, respectively, average birth weights...
Background mTOR inhibitors have activity in pediatric tumor models. A phase I trial of the inhibitor temsirolimus (TEM) with irinotecan (IRN) and temozolomide (TMZ) was conducted children recurrent/refractory solid tumors, including central nervous system (CNS) tumors. Methods Escalating doses intravenous (IV) TEM were administered on days 1 8 21‐day cycles. IRN (50 mg/m 2 /dose escalated to a maximum 90 /dose) TMZ (100 150 orally (PO) 1–5. When tolerated (MTD) identified, frequency...
Abstract Background Poly(ADP‐ribose) polymerase (PARP) signals DNA damage and facilitates repair. PARP inhibitors are being evaluated in cancers with defective repair mechanisms or combination cytotoxic therapy radiation. We the inhibitor, olaparib, chemotherapy using vitro vivo pediatric solid tumor models. Procedure The IC 50 of olaparib alone agents was determined 10 cell lines. Synergy assessed index Chou‐Talalay. Olaparib topotecan/cyclophosphamide xenograft models Ewing sarcoma (RD‐ES)...
ABSTRACT Adolescents and young adults (AYAs) with cancer face unique demands, which result in barriers to psychosocial/behavioral trial retention. Theory‐informed patient‐engaged strategies have the potential increase The purpose of this manuscript is illustrate how partner AYAs leverage Theoretical Domains Framework identify retention behavior change techniques (BCTs) targeting these create strategies. Exemplar developed using approach implemented our an adherence‐promotion intervention are...
Isolated limb infusion with melphalan is a well-tolerated treatment for patients in-transit extremity melanoma an approximately 30% complete response (CR) rate. ADH-1 cyclic pentapeptide that disrupts N-cadherin adhesion complexes and when given systemically in preclinical model of regional therapy demonstrated synergistic antitumor activity. A phase 1 dose escalation study to evaluate the safety, tolerability, pharmacokinetics, activity systemic combination via isolated was performed.Dose...
Aim The aim of the present study was to characterize pharmacokinetics oral proteasome inhibitor, ixazomib, in patients with solid tumours and moderate or severe hepatic impairment, provide posology recommendations. Methods Eligible adults advanced malignancies for which no further effective therapy available received a single dose ixazomib on day 1 pharmacokinetic cycle; normal function, impairment 4 mg, 2.3 mg 1.5 respectively. Blood samples single‐dose characterization were collected over...
Abstract Background Cyclin D has been shown to play an essential role in acute lymphoblastic leukemia (ALL) initiation and progression, providing rationale for targeting the CDK4/6‐cyclin complex that regulates cell cycle progression. Procedure The Children's Oncology Group AINV18P1 phase 1 trial evaluated CDK4/6 inhibitor, palbociclib, combination with standard four‐drug re‐induction chemotherapy children young adults relapsed/refractory B‐ T‐cell lymphoma. Palbociclib (50 mg/m 2 /dose) was...
Background EZN-2208 is a water-soluble PEGylated conjugate of the topoisomerase inhibitor SN38, active metabolite irinotecan. Compared to irinotecan, has prolonged half-life permitting extended exposure SN38. demonstrated clinical tolerability and antitumor activity in adults with advanced solid tumors. This Phase 1 study evaluated safety, pharmacokinetics, preliminary children relapsed or refractory Procedure was administered as 1-hour intravenous infusion once every 21 days at five dose...
Adherence promotion is a critical component of adolescent and young adult (AYA) cancer care, but predictors nonadherence that could be targeted in intervention efforts remain largely unknown. The purpose this multi-site longitudinal observational study was to examine the relationship between barriers medication adherence among AYAs with cancer.Sixty-five (ages 15-24 years; mean age = 18.97 years, SD 2.51; Mmean time since diagnosis 1.42 1.95) newly diagnosed or relapsed completed self-report...
Summary Venetoclax (VEN) combined with hypomethylating agents (HMA) decitabine or azacitidine is used for adult acute myeloid leukaemia (AML), but its application in paediatric, adolescent and young (AYA) AML lacks prospective studies. We performed a retrospective chart review of paediatric AYA patients treated HMA + VEN at Cincinnati Children's Hospital Medical Centre. Twenty‐seven received 30 treatment courses relapsed/refractory (R/R, n = 21) newly diagnosed ( 9) due to ineligibility...
Abstract Background Ontuxizumab is a humanized IgG monoclonal antibody that targets the cell‐surface glycoprotein endosialin (tumor endothelial marker‐1[TEM‐1]/CD248) found on activated mesenchymal cells and certain tumors. binding to may interfere with platelet‐derived growth factor signaling, prevent tumor stroma organization, new vessel formation. Methods was administered intravenously days 1, 8, 15, 22 of 28‐day cycle at three dose levels (4, 12 mg/kg). Further escalation 16 mg/kg...
Bridging therapy (BT) given during the period between T-cell collection and initiation of lymphodepleting chemotherapy is indicated for most children with B-cell acute lymphoblastic leukemia (B-ALL) undergoing treatment tisagenlecleucel (tisa-cel), a CD19-directed chimeric antigen receptor (CAR-T) therapy. Both conventional agents directed antibody-based therapies such as antibody-drug conjugates bispecific engagers have been used systemic forms BT. The purpose this retrospective study was...
Outcomes for children and adolescents with relapsed refractory Hodgkin lymphoma (HL) are poor, ∼50% of patients experiencing a subsequent relapse. The anti-CD30 antibody-drug conjugate brentuximab vedotin improved progression-free survival (PFS) when used as consolidation after autologous stem cell transplantation (ASCT) in adults high-risk relapsed/refractory HL. Data on consolidative therapy ASCT pediatric HL extremely limited, data only 11 reported the literature. We performed...